Meridian Interstate Bancorp (EBSB) 25.60 $EBSB
Meridian Interstate Bancorp (EBSB) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 8:13AM CDT
Meridian Interstate Bancorp (EBSB) Enters Oversold Territory
Shares of Sallie Mae Tank with Spin-off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 4:10PM CDT
Following the announcement of the completion of its long proposed strategic plan to split its operation, shares of Sallie Mae (SLM), formally known as SLM Corporation, plunged more than 60% on May 1
Meridian Interstate Bancorp, Inc. Reports Net Income for the First Quarter Ended March 31, 2014
GlobeNewswire - Tue Apr 22, 3:18PM CDT
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian"
(Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank" , which also operates under the name Mt. Washington Bank, a Division of East Boston Savings Bank ("Mt. Washington" , announced net income of $4.8 million, or $0.22 per diluted share, for the quarter ended March 31, 2014, up from $3.1 million, or $0.14 per diluted share, for the quarter ended March 31, 2013. The Company's return on average assets was 0.70% for the quarter ended March 31, 2014, up from 0.53% for the quarter ended March 31, 2013. For the quarter ended March 31, 2014, the Company's return on average equity was 7.59%, up from 5.20% for the quarter ended March 31, 2013.
Balanced View on Sallie Mae - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:45PM CDT
We believe that its leading position in the student lending market, diversifying efforts and increasing private student loan originations will help it to navigate well through the current sluggish growth cycle.
Hudson City Shows Stability in Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 10:10AM CDT
On Mar 26, 2014, we issued an updated research report on New Jersey based Savings & Loan institution Hudson City Bancorp, Inc
Washington Federal Continues with Inorganic Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 9:00AM CDT
On March 24, 2014, we issued an updated research report on Washington Federal. The company has been growing and enhancing its market share inorganically.
Uptrend Call Working As Meridian Interstate Bancorp Stock Rises 14.9% (EBSB)
Comtex SmarTrend(R) - Fri Mar 21, 11:14AM CDT
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.68. In approximately 2 months, Meridian Interstate Bancorp has returned 14.89% as of today's recent price of $27.20.
HopFed Shares Hit 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 2:20PM CDT
Riding on a steady growth momentum, shares of HopFed Bancorp Inc. reached a 52-week high of $11.75 on Mar 13.
Meridian Interstate Bancorp Up 14.9% Since SmarTrend Uptrend Call (EBSB)
Comtex SmarTrend(R) - Fri Mar 14, 9:53AM CDT
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.67. In approximately 2 months, Meridian Interstate Bancorp has returned 14.89% as of today's recent price of $27.20.
Book Profits With These 11 Community Banks
at The Street - Thu Mar 13, 1:50PM CDT
Investors should avoid Eagle Bancorp, Home Bancshares, Investors Bancorp, Bank of the Ozarks and Signature Bank .
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:46AM CDT
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)?
Meridian Interstate Bancorp Has Returned 17.2% Since SmarTrend Recommendation (EBSB)
Comtex SmarTrend(R) - Fri Mar 07, 9:25AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.68. In approximately 2 month, Meridian Interstate Bancorp has returned 17.21% as of today's recent price of $27.75.
Meridian Interstate Bancorp, Inc. Announces Adoption of Plan of Conversion for Second-Step Stock Offering
GlobeNewswire - Wed Mar 05, 4:45PM CST
Meridian Interstate Bancorp, Inc. (the "Company" (Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank" , announced today that its Board of Directors, together with the Board of Trustees of Meridian Financial Services, Incorporated (the "MHC" and the Board of Directors of the Bank, have adopted a Plan of Conversion pursuant to which the Company will reorganize into a new stock holding company and will conduct a second-step stock offering of new shares of common stock.
Weakness Seen in Pulaski Financial (PULB) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:58AM CST
Pulaski Financial has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Kearny Financial Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 5:40PM CST
On Feb 12, Zacks Investment Research upgraded Kearny Financial Corp to a Zacks Rank #1 (Strong Buy).
Riverview Bancorp Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 2:26PM CST
Shares of Riverview Bancorp Inc. crafted a new 52-week high, touching $3.30 at the closing of the trading session on Feb 7
Meridian Interstate Bancorp, Inc. Reports Net Income for the Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Tue Jan 28, 3:15PM CST
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian" (Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank" , which also operates under the name Mt. Washington Bank, a Division of East Boston Savings Bank ("Mt. Washington" , announced net income of $4.0 million, or $0.18 per diluted share, for the quarter ended December 31, 2013, up from $2.1 million, or $0.10 per diluted share, for the quarter ended December 31, 2012. For the year ended December 31, 2013, net income was $15.4 million, or $0.70 per diluted share, up from $12.4 million, or $0.57 per diluted share, for the year ended December 31, 2012. The Company's return on average assets was 0.60% for the quarter ended December 31, 2013, up from 0.38% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average assets was 0.62%, up from 0.59% for the year ended December 31, 2012. The Company's return on average equity was 6.49% for the quarter ended December 31, 2013, up from 3.59% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average equity was 6.39%, up from 5.42% for the year ended December 31, 2012.
2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9nmsl/opportunityanalyze) has announced the addition of the "2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017" report to their offering. Cystic Fibrosis is caused by a genetic mutation which leads to the production of thickened sticky secretions in organs with epithelial cell linings, including the respiratory tract. Over time, lung infections lead to airway destruction, respiratory failure and death. The first-in-class CFTR modulator Kalydeco, a CFTR potentiator works to restore the function of the mutated CFTR protein in patients with the G551D gating mutation of CF, allowing an improved flow of salt and fluids on the surface of the lungs. Only around 4% of CF patients in the US have the G551D gating mutation, and more studies are needed to help determine whether people with other CF gating mutations might also be eligible for Kalydeco. Still, the drug's approval has paved the way for a new class of therapies, which offer a personalized treatment approach to patients and could be highly profitable for its developers. Vertex is now developing a combination therapy of potential first-in-class CFTR modulator lumacaftor (VX-809) with Kalydeco (VX-770) for the treatment of CF patients who are homozygous for the F508del mutation in the CFTR gene. The CFTR corrector, lumacaftor increases trafficking of the defective CFTR protein to the cell membrane, where it can exert its functions. The combination therapy is currently in Phase III stage of development, and is expected to gain approval in 2014. It is estimated that around half of all CF patients are homozygous to the F508del mutation, and Vertex has also announced plans to explore the lumacaftor/Kalydeco combination therapy in patients that are heterozygous to the F508del mutation. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/x9...ityanalyze
Moody's May Downgrade First Niagara Ratings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 2:55PM CST
Moody's Investors Service - the credit rating arm of Moody's Corp. has placed the ratings of First Niagara Financial Group Inc. and its affiliates on review for a possible downgrade.
Zacks #1 Rank Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy" List for Wednesday
Meridian Interstate Bancorp (EBSB) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 8:13AM CDT
Meridian Interstate Bancorp (EBSB) Enters Oversold Territory
Shares of Sallie Mae Tank with Spin-off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 4:10PM CDT
Following the announcement of the completion of its long proposed strategic plan to split its operation, shares of Sallie Mae (SLM), formally known as SLM Corporation, plunged more than 60% on May 1
Meridian Interstate Bancorp, Inc. Reports Net Income for the First Quarter Ended March 31, 2014
GlobeNewswire - Tue Apr 22, 3:18PM CDT
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian"
(Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank" , which also operates under the name Mt. Washington Bank, a Division of East Boston Savings Bank ("Mt. Washington" , announced net income of $4.8 million, or $0.22 per diluted share, for the quarter ended March 31, 2014, up from $3.1 million, or $0.14 per diluted share, for the quarter ended March 31, 2013. The Company's return on average assets was 0.70% for the quarter ended March 31, 2014, up from 0.53% for the quarter ended March 31, 2013. For the quarter ended March 31, 2014, the Company's return on average equity was 7.59%, up from 5.20% for the quarter ended March 31, 2013. Balanced View on Sallie Mae - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:45PM CDT
We believe that its leading position in the student lending market, diversifying efforts and increasing private student loan originations will help it to navigate well through the current sluggish growth cycle.
Hudson City Shows Stability in Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 10:10AM CDT
On Mar 26, 2014, we issued an updated research report on New Jersey based Savings & Loan institution Hudson City Bancorp, Inc
Washington Federal Continues with Inorganic Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 9:00AM CDT
On March 24, 2014, we issued an updated research report on Washington Federal. The company has been growing and enhancing its market share inorganically.
Uptrend Call Working As Meridian Interstate Bancorp Stock Rises 14.9% (EBSB)
Comtex SmarTrend(R) - Fri Mar 21, 11:14AM CDT
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.68. In approximately 2 months, Meridian Interstate Bancorp has returned 14.89% as of today's recent price of $27.20.
HopFed Shares Hit 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 2:20PM CDT
Riding on a steady growth momentum, shares of HopFed Bancorp Inc. reached a 52-week high of $11.75 on Mar 13.
Meridian Interstate Bancorp Up 14.9% Since SmarTrend Uptrend Call (EBSB)
Comtex SmarTrend(R) - Fri Mar 14, 9:53AM CDT
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.67. In approximately 2 months, Meridian Interstate Bancorp has returned 14.89% as of today's recent price of $27.20.
Book Profits With These 11 Community Banks
at The Street - Thu Mar 13, 1:50PM CDT
Investors should avoid Eagle Bancorp, Home Bancshares, Investors Bancorp, Bank of the Ozarks and Signature Bank .
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:46AM CDT
Can The Uptrend Continue for Meridian Interstate Bancorp (EBSB)?
Meridian Interstate Bancorp Has Returned 17.2% Since SmarTrend Recommendation (EBSB)
Comtex SmarTrend(R) - Fri Mar 07, 9:25AM CST
SmarTrend identified an Uptrend for Meridian Interstate Bancorp (NASDAQ:EBSB) on January 21st, 2014 at $23.68. In approximately 2 month, Meridian Interstate Bancorp has returned 17.21% as of today's recent price of $27.75.
Meridian Interstate Bancorp, Inc. Announces Adoption of Plan of Conversion for Second-Step Stock Offering
GlobeNewswire - Wed Mar 05, 4:45PM CST
Meridian Interstate Bancorp, Inc. (the "Company"
(Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank" , announced today that its Board of Directors, together with the Board of Trustees of Meridian Financial Services, Incorporated (the "MHC" and the Board of Directors of the Bank, have adopted a Plan of Conversion pursuant to which the Company will reorganize into a new stock holding company and will conduct a second-step stock offering of new shares of common stock. Weakness Seen in Pulaski Financial (PULB) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:58AM CST
Pulaski Financial has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Kearny Financial Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 5:40PM CST
On Feb 12, Zacks Investment Research upgraded Kearny Financial Corp to a Zacks Rank #1 (Strong Buy).
Riverview Bancorp Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 2:26PM CST
Shares of Riverview Bancorp Inc. crafted a new 52-week high, touching $3.30 at the closing of the trading session on Feb 7
Meridian Interstate Bancorp, Inc. Reports Net Income for the Fourth Quarter and Year Ended December 31, 2013
GlobeNewswire - Tue Jan 28, 3:15PM CST
Meridian Interstate Bancorp, Inc. (the "Company" or "Meridian"
(Nasdaq:EBSB), the holding company for East Boston Savings Bank (the "Bank" , which also operates under the name Mt. Washington Bank, a Division of East Boston Savings Bank ("Mt. Washington" , announced net income of $4.0 million, or $0.18 per diluted share, for the quarter ended December 31, 2013, up from $2.1 million, or $0.10 per diluted share, for the quarter ended December 31, 2012. For the year ended December 31, 2013, net income was $15.4 million, or $0.70 per diluted share, up from $12.4 million, or $0.57 per diluted share, for the year ended December 31, 2012. The Company's return on average assets was 0.60% for the quarter ended December 31, 2013, up from 0.38% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average assets was 0.62%, up from 0.59% for the year ended December 31, 2012. The Company's return on average equity was 6.49% for the quarter ended December 31, 2013, up from 3.59% for the quarter ended December 31, 2012. For the year ended December 31, 2013, the Company's return on average equity was 6.39%, up from 5.42% for the year ended December 31, 2012. 2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
M2 - Wed Jan 22, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9nmsl/opportunityanalyze) has announced the addition of the "2013 Report on Global Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017" report to their offering. Cystic Fibrosis is caused by a genetic mutation which leads to the production of thickened sticky secretions in organs with epithelial cell linings, including the respiratory tract. Over time, lung infections lead to airway destruction, respiratory failure and death. The first-in-class CFTR modulator Kalydeco, a CFTR potentiator works to restore the function of the mutated CFTR protein in patients with the G551D gating mutation of CF, allowing an improved flow of salt and fluids on the surface of the lungs. Only around 4% of CF patients in the US have the G551D gating mutation, and more studies are needed to help determine whether people with other CF gating mutations might also be eligible for Kalydeco. Still, the drug's approval has paved the way for a new class of therapies, which offer a personalized treatment approach to patients and could be highly profitable for its developers. Vertex is now developing a combination therapy of potential first-in-class CFTR modulator lumacaftor (VX-809) with Kalydeco (VX-770) for the treatment of CF patients who are homozygous for the F508del mutation in the CFTR gene. The CFTR corrector, lumacaftor increases trafficking of the defective CFTR protein to the cell membrane, where it can exert its functions. The combination therapy is currently in Phase III stage of development, and is expected to gain approval in 2014. It is estimated that around half of all CF patients are homozygous to the F508del mutation, and Vertex has also announced plans to explore the lumacaftor/Kalydeco combination therapy in patients that are heterozygous to the F508del mutation. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 R&D Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/x9...ityanalyze
Moody's May Downgrade First Niagara Ratings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 2:55PM CST
Moody's Investors Service - the credit rating arm of Moody's Corp. has placed the ratings of First Niagara Financial Group Inc. and its affiliates on review for a possible downgrade.
Zacks #1 Rank Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 7:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy"
List for Wednesday 
